Does Oral Minoxidil Work for Hair Loss?
This is a research-based fact check, not medical advice. The findings summarized here come from peer-reviewed studies and are presented without added opinions. Consult a certified healthcare practitioner before making any treatment decision.
Verdict
Yes, oral minoxidil works for hair loss based on clinical evidence. Across 27 studies involving 2,933 patients, 47% showed hair improvement and 35% showed significant improvement. In 4 controlled head-to-head trials, oral minoxidil produced hair density improvements comparable to topical minoxidil 5%, with no statistically significant difference between the two forms. It is used off-label and is not FDA-approved for hair loss.
Key takeaways
- Yes, oral minoxidil works for hair loss based on clinical study data across more than 2,900 patients.
- 47% of patients showed hair improvement and 35% showed significant improvement across 27 studies.
- In controlled trials, oral minoxidil matched topical minoxidil 5% for hair density improvement with no statistically significant difference.
- Efficacy is dose-dependent: higher doses generally produce better results but also more side effects.
- It works for both men and women with pattern hair loss.
- Oral minoxidil is not FDA-approved for hair loss and must be prescribed off-label.
Clinical evidence for hair regrowth
A 2025 meta-analysis of 27 studies covering 2,933 patients found that oral minoxidil produced measurable hair improvement in 47% of patients and significant improvement in 35%. Only 26% had stable disease without improvement, and the studies reported no cases where hair loss worsened on treatment. Oral minoxidil is one of several treatment options reviewed in our hair restoration guide, and a full overview of this drug class is in our oral minoxidil category guide.
In controlled head-to-head trials specifically comparing oral minoxidil against topical minoxidil 5%, both forms produced similar improvements in hair density and hair diameter. A 2025 meta-analysis of 4 randomised controlled trials (279 patients) found no statistically significant difference in hair density improvement between oral and topical minoxidil.
Efficacy rates from clinical studies
The results from clinical studies can be summarised as: across all available studies, most patients see some degree of improvement, roughly half show measurable hair gains, and about one third achieve significant improvement. These numbers come from a mix of study types including both controlled trials and observational studies, which affects how precisely the rates can be interpreted.
Efficacy is dose-dependent. Studies consistently show that higher doses produce greater hair improvements, though they also increase the risk of side effects such as unwanted body hair growth. A 2024 comprehensive review found the 1mg daily dose was effective and safe, while higher doses showed progressively better results up to 5mg daily.
What to expect from treatment
Treatment timeline
Most clinical studies ran for 24 to 39 weeks and reported significant improvements by the end of the study period. This is consistent with topical minoxidil, which also typically requires 3-6 months before visible improvements appear. Initial shedding in the first few weeks is common and is a sign that hair follicles are entering a new growth cycle, not that the treatment is failing.
Measuring improvement
The primary outcome measured in trials is hair density, expressed as number of hairs per square centimetre. In one controlled trial, patients on oral minoxidil 1mg saw total hair count increase from 164.6 to 184.7 hairs per square centimetre over 24 weeks. Terminal hair count (thicker, pigmented hairs) increased from 106.5 to 112.6 hairs per square centimetre in the same period.
In a separate study using 5mg daily in male patients, total hair count increased significantly at both 12 and 24 weeks. Improvement was more pronounced at the vertex (crown area) than the frontal hairline. Global photographic assessments by investigators also showed improvement in the majority of patients.
Efficacy in women
Clinical studies have included both men and women, and the meta-analysis data shows results across both sexes. Female patients in trials typically use lower doses (0.25-2.5mg daily) compared to men (1-5mg daily). One small controlled trial found that 1mg daily was more effective than 0.25mg daily in women with female pattern hair loss, suggesting the same dose-dependent response applies to women.
Women should be aware that oral minoxidil is contraindicated during pregnancy and carries a higher risk of unwanted body hair growth (hypertrichosis) than men at equivalent doses.
Comparison with topical minoxidil
In controlled trials, the two forms produce comparable hair density results. The 2025 meta-analysis of 4 RCTs found no statistically significant difference in hair density improvement between oral minoxidil and topical minoxidil 5% solution. The main trade-off is side effects: oral minoxidil caused twice as much unwanted body hair growth compared to topical in the same trials. A full breakdown of the differences is in our oral vs topical minoxidil comparison, and a detailed look at the side effect rates is in our oral minoxidil side effects guide.
For patients who cannot tolerate scalp application of topical minoxidil or find it inconvenient, oral minoxidil offers a comparable efficacy option. For patients concerned about systemic side effects, topical minoxidil remains the FDA-approved first choice.
Comparison with finasteride
Direct comparisons are limited. A network meta-analysis found that oral dutasteride 0.5mg was likely the most effective monotherapy for male pattern hair loss, with finasteride and various forms of minoxidil performing at roughly comparable levels in indirect comparisons. Oral minoxidil 5mg and topical minoxidil 5% showed similar efficacy to each other and were broadly competitive with finasteride 1mg, though head-to-head trial data is scarce.
The practical comparison also involves mechanism: finasteride works by blocking the hormone (DHT) that causes hair loss, while minoxidil works by stimulating blood flow to hair follicles and extending the growth phase. Many dermatologists use them in combination rather than choosing one over the other.
Evidence at a glance
| Study | Patients | Key finding |
|---|---|---|
| 2024 meta-analysis: oral minoxidil efficacy and safety | Multiple studies pooled | Significant improvement in hair density and growth rate. 1mg daily safe with no serious adverse events. |
| 2025 meta-analysis: oral vs topical minoxidil | 257 patients (4 RCTs) | No significant difference in hair density improvement vs topical 5%. Higher hypertrichosis with oral. |
| Liu et al. 2025 single-arm meta-analysis | 2,933 patients (27 studies) | 47% showed improvement, 35% showed significant improvement. |
What the research cannot tell you
- Whether oral minoxidil will work for you specifically. Response rates vary and no predictor of individual response exists.
- How results compare beyond 39 weeks. No long-term controlled trial data exists for hair loss use.
- How oral minoxidil performs head-to-head against finasteride in a randomised trial.
- Whether stopping treatment causes hair loss to return to baseline. Limited discontinuation data exists.
- The optimal dose for your specific hair loss pattern or severity.